<svg id="Layer_1" data-name="Layer 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 303 303"><defs><style>.cls-1{font-size:20px;font-weight:700;}.cls-1,.cls-2,.cls-3{font-family:Helvetica;}.cls-2{font-size:21px;}.cls-3{font-size:18px;}.cls-4{white-space:pre;}.cls-5,.cls-6{fill:none;stroke-miterlimit:10;}.cls-5{stroke:#666;stroke-width:0.75px;}.cls-6{stroke:#a15e56;stroke-width:3px;}</style></defs><title>biofeedback-pros</title><text class="cls-1" transform="translate(92.04 44.67)">Biofeedback</text><text class="cls-2" transform="translate(123.5 94.7)">PROS</text><text class="cls-3" transform="translate(52.94 138.39)">A<tspan class="cls-4" x="11.02" y="0"> 2005 study from UCL</tspan><tspan x="186.1" y="0">A</tspan><tspan class="cls-4"><tspan x="-41.53" y="21.6"> showed that 77 percent of patients</tspan><tspan x="-3" y="43.2"> who received biofeeback</tspan><tspan x="-26.01" y="64.8"> treatment remained abstinent, </tspan></tspan><tspan x="-7.5" y="86.4">while only 44 percent who </tspan><tspan x="2.51" y="108">didnâ€™t recieve treatment </tspan><tspan x="19.51" y="129.6">remained abstinent.</tspan></text><line class="cls-5" x1="9.87" y1="54.07" x2="293.13" y2="52.75"/><rect class="cls-6" x="1.5" y="1.5" width="300" height="300"/></svg>